EQUILLIUM INC

EQNASDAQ

🏆 #2961 by market capEarnings Aug 13US Equity

$2.23▲ $0.04 (+1.83%)

🌙 After hours$2.23▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 1.8%

7d▲ 2.8%

14d▼ 1.8%

30d▼ 21.8%

1y▲ 139.4%

🏦Market Cap

$141M

Small Cap

📈Revenue Growth (YoY)

-100.0%

Declining

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $2.22 – $2.24
52-Week Range: $0.76 – $3.54
Volume: $7.77B
Avg Volume: $10.30B
Shares Outstanding: 63.2M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $35M
Last Q Revenue: $9M
P/E Ratio: -5.9
P/S Ratio: 0.0x
EPS (TTM): $-0.20
Dividend Yield: 0.00%

Why Investors Own EQ

✓High-growth profile — revenue up +43.0% YoY with expanding US Equity exposure.
✓Healthy economics — 38% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$35M▲ +39.6% YoY

Gross Margin (TTM)

38.4%▲ +1.5% YoY

Operating Income (TTM)

$12M▲ +39.6% YoY

Free Cash Flow (TTM)

$9M▲ +39.6% YoY

About EQUILLIUM INC

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

🦦